Valneva targets 2022 revenue boost on COVID-19 vaccine
[ad_1] The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner Register now for FREE unlimited access to Reuters.com Register Feb 3 (Reuters) – French vaccine developer Valneva (VLS.PA) expects its COVID-19 vaccine candidate to considerably boost its yearly sales in 2022, after they already […]
Continue Reading